* 中国生物科技公司--歌礼制药1672.HK周三盘中一度升8.7%，创2019年3月12日以来新高。
* 该公司此前公告称，治疗肥胖症的候选药物ASC47单药疗法澳大利亚Ib期研究中，肥胖症患者单次皮下注射（90毫克）后表现出减重迹象。经安慰剂校准后的平均减重为0.2%（第29天）、1.0%（第43天）以及1.7%（第50天，峰值）。
* 歌礼制药今年迄今暴涨157.1%，同期恒生指数.HSI大幅上扬17.8%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度跌0.6%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 吴云凌)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.